Clinical Trial Update: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing Telisotuzumab vedotin versus docetaxel in adults with previously treated non-squamous non-small cell lung cancer, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Snippet

Sponsor: AbbVie | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: RECRUITING